81210

BRAF gene analysis, V600 variant(s)

CPT 81210 refers to the molecular genetic testing of the BRAF (B-Raf proto-oncogene, serine/threonine kinase) gene, specifically targeting variants at the V600 codon, such as V600E, V600K, V600D, and V600R. The BRAF gene encodes a protein that is a critical component of the MAP kinase/ERK signaling pathway, which is responsible for regulating essential cellular processes including growth, differentiation, and survival. Mutations within this gene, particularly at the V600 position, lead to a constitutively active BRAF protein. This chronic activation causes uncontrolled cellular proliferation and plays a major role in the pathogenesis of various malignancies. This laboratory procedure is most frequently performed on tumor tissue specimens, typically formalin-fixed, paraffin-embedded (FFPE) blocks or slides obtained from biopsies or surgical resections of malignant melanoma, colorectal cancer, or non-small cell lung cancer. In patients with cutaneous melanoma, the identification of a BRAF V600 mutation is a standard of care requirement to determine eligibility for targeted therapies, such as BRAF inhibitors (e.g., vemurafenib, dabrafenib) often used in combination with MEK inhibitors. In the setting of metastatic colorectal cancer, BRAF status serves as both a prognostic marker and a predictive tool; patients with V600E mutations generally have a poorer prognosis and are less likely to benefit from anti-EGFR antibody therapies like cetuximab or panitumumab. Furthermore, BRAF testing is used in the workup of colorectal cancers with microsatellite instability (MSI) to help distinguish sporadic cases from Lynch syndrome. The testing process involves DNA extraction from the clinical specimen, followed by amplification via polymerase chain reaction (PCR) and detection through specific methodologies such as allele-specific PCR, Sanger sequencing, or pyrosequencing. This molecular analysis provides vital genomic data to facilitate personalized oncology treatment plans.

Clinical Indications

  • Assessment of metastatic melanoma to determine eligibility for BRAF and MEK inhibitor therapy.
  • Prognostic stratification of patients with metastatic colorectal cancer.
  • Evaluation of colorectal cancer specimens with high microsatellite instability (MSI-H) to rule out Lynch syndrome (BRAF V600E suggests sporadic origin).
  • Therapeutic selection for patients with advanced non-small cell lung cancer (NSCLC).
  • Risk stratification and prognostic assessment of papillary thyroid carcinoma.
  • Diagnostic confirmation of hairy cell leukemia in patients with atypical presentations.
  • Monitoring of minimal residual disease or treatment response in known BRAF-mutated malignancies.

Procedure Steps

  1. Accessioning of the clinical specimen (tissue block, slides, or aspirate) and verification of patient identity.
  2. Pathological review of the hematoxylin and eosin (H&E) stained slide to identify the tumor area.
  3. Estimation of tumor cellularity to ensure the specimen meets the minimum threshold for DNA detection.
  4. Macrodissection or microdissection of the designated tumor-rich area from the tissue section.
  5. Cell lysis and DNA extraction using standardized laboratory protocols.
  6. Purification and quantification of the extracted DNA to verify adequate concentration and quality.
  7. Amplification of the target BRAF gene region (specifically Exon 15, codon 600) using Polymerase Chain Reaction (PCR).
  8. Detection and identification of V600 variants using techniques such as allele-specific PCR, pyrosequencing, or fragment analysis.
  9. Bioinformatic analysis of the raw data to confirm the presence or absence of specific variants.
  10. Final interpretation of results by a qualified molecular pathologist or clinical laboratory director.
  11. Generation of a comprehensive clinical report including methodology, findings, and clinical significance.

Coding Guidelines

  • CPT 81210 is a Tier 1 molecular pathology procedure code.
  • This code should be reported only once per procedure, regardless of the specific number of V600 variants (e.g., V600E, V600K) being tested.
  • Do not report 81210 if the BRAF analysis is part of a larger genomic sequencing procedure (GSP) or multi-gene panel for solid tumors, such as 81445 or 81450.
  • For BRAF variants other than V600, use the appropriate Tier 2 code (e.g., 81404) or an unlisted molecular pathology code if applicable.
  • Check payer-specific policies regarding the use of modifier 26 (professional component) versus the technical component, as many molecular pathology codes are considered 'global' in the laboratory setting.
  • If the test is performed on a specimen other than tumor tissue (e.g., liquid biopsy/cell-free DNA), ensure the code still matches the variant analysis described.

Associated ICD-10 Codes